Pemvidutide
In clinical trials for weight and liver-fat research — not yet FDA-approved.
What it's for
In clinical trials for weight and liver-fat research — not yet FDA-approved.
What it's for
Pemvidutide is a lab-made investigational peptide designed to turn on both GLP-1 (a gut hormone signal for fullness and blood-sugar handling) and glucagon receptors (landing spots on cells). It is being studied, not sold as an approved everyday medicine.
What it does for the body
Clinical programs have explored weight reduction and liver-fat (including MASH/NASH research contexts). It is not approved to treat obesity or liver disease yet. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
GLP-1 (a gut hormone signal for fullness and blood-sugar handling) signaling supports appetite and sugar handling; glucagon pathway activity is being studied for energy use and liver-fat effects. Think two related hormone levers pulled at once — still under testing.
Research context
mid-stage human human data exist; large late-stage human confirmation pending. Educational summary only — not medical advice.
Studied for (literature interest)
- MASH / fatty liver (investigational)
- Obesity (investigational)
Cautions (educational)
- Not FDA-approved.
- DrPep does not offer medical consultations, dosing, or sales.
Citations / starters
- IMPACT Phase 2b MASH trial coverage (Noureddin et al., The Lancet, 2025) — DOI 10.1016/S0140-6736(25)02114-2
- Phase 1b/2a fatty-liver study (Browne et al., JHEP Reports, 2025) — DOI 10.1016/j.jhepr.2025.101483
- PubMed search: Pemvidutide — NCBI PubMed
- ClinicalTrials.gov search: Pemvidutide — U.S. clinical trials registry
- FDA search: Pemvidutide — FDA.gov